The effect of ticagrelor on the metabolism of midazolam in healthy volunteers

Clinical Therapeutics

Volumn 35, Issue 7, 2013, Pages 1025-1037

  Teng, Renli ^a   Butler, Kathleen ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

CYP3A; Midazolam; Pharmacokinetics; Ticagrelor

Indexed keywords

1 HYDROXYMIDAZOLAM; 4 HYDROXYMIDAZOLAM; DRUG METABOLITE; MIDAZOLAM; PLACEBO; TICAGRELOR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

CYP3A; MIDAZOLAM; PHARMACOKINETICS; TICAGRELOR;

ADENOSINE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDAZOLAM; MIDDLE AGED; YOUNG ADULT;

EID: 84880431885     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.06.003     Document Type: Article

References (29)

1. Kumar A., Cannon C.P. Acute coronary syndromes: diagnosis and management. Mayo Clin Proc 2009, 84:917-938.
2. Taneva E., Bogdanova V., Shtereva N. Acute coronary syndrome, comorbidity, and mortality in geriatric patients. Ann N Y Acad Sci 2004, 1019:106-110.
3. Hamm C.W., Bassand J.-P., Agewall S., et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011, 32:2999-3054.
4. Ament P.W., Bertolino J.G., Liszewski J.L. Clinically significant drug interactions. Am Fam Physician 2000, 61:1745-1754.
5. Food and Drug Administration (FDA). Drug interaction studies-study design, data analysis, and implications for dosing and labelling. US Department of Health and Human Services. Food and Drug Administration. September 2006. Accessed February 13, 2012. http://www.fda.gov/downloads/Drugs/.../Guidances/ucm072101.pdf.%20%20Accessed%2030%20August%202011.
6. Zanger U.M., Turpeinen M., Klein K., Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug transformation. Anal Bioanal Chem 2008, 392:1093-1108.
7. Zhou S.F., Xue C.C., Yu X.Q., et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007, 29:687-710.
8. Levine G.N., Bates E.R., Blankenship J.C., et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011, 58:e44-e122.
9. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.
10. Husted S., van Giezen J.J. Ticagrelor: the first reversibly binding oral P2Y receptor antagonist. Cardiovasc Ther 2009, 27:259-274.
11. 12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 2009, 7:1556-1565.
12. Teng R., Oliver S., Hayes M.A., Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 2010, 38:1514-1521.
13. Zhou D., Andersson T.B., Grimm S.W. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome p450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos 2011, 39:703-710.
14. Bjornsson T.D., Callaghan J.T., Einolf H.J., et al. Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003, 43:443-469.
15. Gorski J.C., Hall S.D., Jones D.R., et al. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994, 47:1643-1653.
16. Patki K.C., von Moltke L.L., Greenblatt D.J. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: role of CYP3A4 and CYP3A5. Drug Metab Dispos 2003, 31:938-944.
17. Thummel K.E., O'Shea D., Paine M.F., et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996, 59:491-502.
18. Palkama V.J., Ahonen J., Neuvonen P.J., Olkkola K.T. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther 1999, 66:33-39.
19. Husted S., Emanuelsson H., Heptinstall S., et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006, 27:1038-1047.
20. Pentikis H.S., Connolly M., Trapnell C.B., et al. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy 2007, 27:1361-1369.
21. Sillén H., Cook M., Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878:2299-2306.
22. Wijnen P.A., Op den Buijsch R.A., Drent M., et al. The prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment Pharmacol Ther 2007, 26(Suppl 2):211-219.
23. Zhou S.F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008, 9:310-322.
24. Penzak S.R., Busse K.H., Robertson S.M., et al. Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions. J Clin Pharmacol 2008, 48:671-680.
25. Schwagmeier R., Alincic S., Striebel H.W. Midazolam pharmacokinetics following intravenous and buccal administration. Br J Clin Pharmacol 1998, 46:203-206.
26. Butler K., Teng R Pharmacokinetics pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol 2010, 70:65-77.
27. Thummel K.E., Wilkinson G.R. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol 1998, 38:389-430.
28. Butler K., Teng R. Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers. Curr Med Res Opin 2011, 27:1585-1593.
29. Teng R., Mitchell P.D., Butler K.A. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol 2013, 69:477-487.